Related Experiment Videos
Hepatitis B vaccination in preterm infants
Insights
Hepatitis B vaccination is safe and effective for preterm infants. Two different vaccination schedules showed similar immunogenicity, supporting current recommendations for premature babies.
Area of Science:
- Immunology
- Pediatrics
- Vaccinology
Background:
- Hepatitis B remains a significant global health concern.
- Preterm infants may have altered immune responses to vaccinations.
- Evaluating vaccine schedules in vulnerable populations is crucial.
Purpose of the Study:
- To assess the immunogenicity and safety of hepatitis B vaccination in preterm infants.
- To compare two different vaccination schedules for preterm infants.
- To determine if current recommendations are effective for premature babies.
Main Methods:
- 85 preterm infants received recombinant hepatitis B vaccine (5 micrograms/dose).
- Group A (<2000 g birthweight) received doses at 1, 2, and 7 months.
- Group B (>=2000 g birthweight) received doses at 0, 1, and 6 months.
Main Results:
- Protective antibody levels were achieved in 95% of Group A and 90% of Group B.
- No significant difference in seropositive rates or antibody concentrations between groups.
- Immune response in preterm infants was comparable to term infants.
Conclusions:
- Preterm infants can be effectively vaccinated against hepatitis B using two distinct schedules.
- A birthweight cutoff of 2000 g can guide vaccination timing.
- Current hepatitis B vaccination strategies are suitable for preterm infants.
Aim:
To investigate the immunogenicity and safety of existing recommendations for hepatitis B vaccination in preterm infants.
Methods:
Recombinant hepatitis B vaccine (H-B-VAX II, 5 micrograms per dose) was given to 85 preterm infants divided into two groups, using two different schedules. Forty four group A infants with birthweights of < 2000 g received three doses at 1, 2, and 7 months of age. Forty one group B infants with birthweights of > or = 2000 g received three doses at 0, 1, and 6 months of age.
Results:
After vaccination, 42 infants from group A (95%) and 37 infants from group B (90%) developed protective levels of antibody. The final seropositive rate and the geometric mean concentration of hepatitis B surface antibody between the two groups were not significantly different. The immune response of preterm infants to hepatitis B vaccines was similar to that of term infants in a previous study.
Conclusions:
Preterm infants can be given hepatitis B vaccines using one of the above two different schedules, at a cutoff birthweight of 2000 g.